In the REDEFINE 1 trial, Garvey and colleagues (Aug. 14 issue)1 report the efficacy of combination therapy with cagrilintide and semaglutide (known as CagriSema) in patients with overweight or obesity who did not have diabetes. The authors acknowledge the predominance of female participants as a limitation. However, this sex distribution aligns with previous trials involving patients with obesity who did not have diabetes, such as those from the STEP Program,2 in which women are frequently overrepresented. Conversely, trials involving patients with type 2 diabetes, including the REDEFINE 2 trial by Davies et al. (Aug. 14 issue),3 more commonly have enrolled men
Fogacci, F., Cicero, A.F.G. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity. THE NEW ENGLAND JOURNAL OF MEDICINE, 393(20), 2065-2066 [10.1056/NEJMc2513141].
Cagrilintide-Semaglutide in Adults with Overweight or Obesity
Cicero AFG
Ultimo
Conceptualization
2025
Abstract
In the REDEFINE 1 trial, Garvey and colleagues (Aug. 14 issue)1 report the efficacy of combination therapy with cagrilintide and semaglutide (known as CagriSema) in patients with overweight or obesity who did not have diabetes. The authors acknowledge the predominance of female participants as a limitation. However, this sex distribution aligns with previous trials involving patients with obesity who did not have diabetes, such as those from the STEP Program,2 in which women are frequently overrepresented. Conversely, trials involving patients with type 2 diabetes, including the REDEFINE 2 trial by Davies et al. (Aug. 14 issue),3 more commonly have enrolled menI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
